Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Dec 05, 2015 5:53pm

337 Views

Post# 24358178

RE:RE:RE:RE:Zenith Notice of Meeting and Management Information Circular

G1945V,

Everything you wrote looks good, but I don't think there is any guarantee that the royalties will flow to shareholders holding Zenith shares that came about from Spinco. I think the allocation of any portion of the royalty to shareholders (via a dividend?) will be at the discretion of the complany. As to "where the 34.4 M shares come from? These belong to Zenith Epigenetics Ltd? Why only 34.4M?" Great questions. I don't know. I guess we'll find out on 1/7/16.

BearDownAZ

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload